(PGEN) –
-
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
-
JPMorgan Downgrades Precigen Inc. (PGEN) to Underweight
-
JMP Securities Reiterates Market Outperform Rating on Precigen Inc. (PGEN)
-
Form 10-K PRECIGEN, INC. For: Dec 31
-
Precigen Inc. (PGEN) reports FY results
-
Form 8-K PRECIGEN, INC. For: Mar 19
-
Precigen Reports Full Year 2023 Financial Results and Business Updates
-
Form 4 PRECIGEN, INC. For: Mar 14 Filed by: KIRK RANDAL J
-
Form 4 PRECIGEN, INC. For: Mar 14 Filed by: Hassan Fred
-
Form 4 PRECIGEN, INC. For: Mar 14 Filed by: Gupta Vinita D
-
Form 4 PRECIGEN, INC. For: Mar 14 Filed by: ALVAREZ CESAR L
-
Form 4 PRECIGEN, INC. For: Mar 14 Filed by: KINDLER JEFFREY B
-
Form 4 PRECIGEN, INC. For: Mar 14 Filed by: MITCHELL DEAN J
-
Form 4 PRECIGEN, INC. For: Mar 14 Filed by: Turley James S
-
Form 4 PRECIGEN, INC. For: Mar 14 Filed by: Frank Steven
-
Form 4 PRECIGEN, INC. For: Mar 09 Filed by: Frank Steven
-
Form 4 PRECIGEN, INC. For: Mar 09 Filed by: MITCHELL DEAN J
-
Form 4 PRECIGEN, INC. For: Mar 09 Filed by: Hassan Fred
-
Form 4 PRECIGEN, INC. For: Mar 09 Filed by: Gupta Vinita D
-
Form 4 PRECIGEN, INC. For: Mar 09 Filed by: ALVAREZ CESAR L
-
Form 4 PRECIGEN, INC. For: Mar 09 Filed by: KINDLER JEFFREY B
-
Form 4 PRECIGEN, INC. For: Mar 09 Filed by: Turley James S
-
Form 4 PRECIGEN, INC. For: Mar 09 Filed by: KIRK RANDAL J
-
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
-
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
-
Form SC 13G/A PRECIGEN, INC. Filed by: Patient Capital Management, LLC
-
Form SC 13G PRECIGEN, INC. Filed by: Patient Capital Management, LLC
-
Form SC 13G/A PRECIGEN, INC. Filed by: Ares Trading S.A.
-
Form 8-K PRECIGEN, INC. For: Feb 02
-
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Form EFFECT PRECIGEN, INC.
-
Precigen (PGEN) Granted FDA Orphan Drug Designation for PRGN-2012
-
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
-
Form 8-K PRECIGEN, INC. For: Jan 08
-
Precigen (PGEN) Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference
-
Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference
-
Precigen Inc. (PGEN) Files $300M Mixed Shelf
-
Form 4 PRECIGEN, INC. For: Dec 28 Filed by: KIRK RANDAL J
-
Form 4 PRECIGEN, INC. For: Dec 28 Filed by: KINDLER JEFFREY B
-
Form S-3 PRECIGEN, INC.
-
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Precigen to Participate in the JMP Securities Hematology and Oncology Summit
-
Form 10-Q PRECIGEN, INC. For: Sep 30
-
Form 8-K PRECIGEN, INC. For: Nov 09
-
Precigen Inc. (PGEN) Reports In-Line Q3 EPS
-
Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs
-
Precigen to Participate in the Stifel 2023 Healthcare Conference
-
Form 4 PRECIGEN, INC. For: Sep 22 Filed by: MITCHELL DEAN J
-
Precigen to Participate in Upcoming Leading Investor and Industry Conferences
-
Form 4 PRECIGEN, INC. For: Aug 23 Filed by: Sabzevari Helen
Back to PGEN Stock Lookup